SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 123 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $356,785 | -20.9% | 24,572 | +14.1% | 0.00% | 0.0% |
Q2 2023 | $450,790 | -8.1% | 21,538 | -7.3% | 0.00% | 0.0% |
Q1 2023 | $490,575 | -23.4% | 23,228 | -7.7% | 0.00% | 0.0% |
Q4 2022 | $640,704 | +21.6% | 25,175 | +14.8% | 0.00% | 0.0% |
Q3 2022 | $527,000 | -22.5% | 21,929 | -38.0% | 0.00% | -50.0% |
Q2 2022 | $680,000 | +64.6% | 35,358 | +48.9% | 0.00% | +100.0% |
Q1 2022 | $413,000 | -1.2% | 23,751 | +27.1% | 0.00% | 0.0% |
Q1 2021 | $418,000 | -37.2% | 18,680 | -37.7% | 0.00% | 0.0% |
Q4 2020 | $666,000 | +5.0% | 29,963 | -30.2% | 0.00% | 0.0% |
Q3 2020 | $634,000 | -4.5% | 42,935 | -4.2% | 0.00% | 0.0% |
Q2 2020 | $664,000 | +462.7% | 44,808 | +317.6% | 0.00% | – |
Q1 2020 | $118,000 | +59.5% | 10,729 | -24.0% | 0.00% | – |
Q1 2019 | $74,000 | -67.5% | 14,117 | -45.8% | 0.00% | – |
Q4 2017 | $228,000 | -41.2% | 26,068 | -21.5% | 0.00% | – |
Q3 2017 | $388,000 | – | 33,189 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |